Centre Hospitalier Universitaire de Rennes

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  Characterization of Muscle Activity During a Surface EMG-controlled Rehabilitation Game

  NCT07838688· Rennes University Hospital· Source

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  Efanesoctocog Prophylaxis Or The Optimization Of Treatment: Real-World Experience Of Taylorizing Clotting Therapy In Hemophilia A

  NCT07830693· Nantes University Hospital· Source

• Not yet recruiting

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source

• Not yet recruiting

  Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· Phase 2· Institut Curie· Source

• Not yet recruiting

  Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial

  NCT07915037· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC

  2026-526300-67-00· Phase 3· Summit Therapeutics Inc.· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years

  NCT07845994· Phase 3· University Hospital, Angers· Source

• Not yet recruiting

  Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial

  NCT07818356· Phase 4· University Hospital, Toulouse· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

  2026-526139-20-00· Phase 3· Kardigan Inc.· Source

• Not yet recruiting

  Follow-up After Oncological Resection by Endoscopic Colorectal ESD (Endoscopic Submucosal Dissection)

  NCT07871227· University Hospital, Bordeaux· Source

• Recruiting

  A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL

  2025-524915-36-00· Phase 1/2· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Not yet recruiting

  Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

  NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Not yet recruiting

  RADIATE-HF - Efficacy and Safety of Cardiac Radiation in Advanced Heart Failure

  NCT07770230· Rennes University Hospital· Source

• Recruiting

  Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)

  NCT07486024· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)

  2024-512763-32-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Not yet recruiting

  Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer

  NCT07828938· Fondation Hôpital Saint-Joseph· Source

• Not yet recruiting

  Stroke Cerebral Reorganization Pathways (SPECTRE)

  NCT06784518· Rennes University Hospital· Source

• Not yet recruiting

  Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial

  NCT07081763· Phase 2· ANRS Maladies Infectieuses Emergentes· Source

• Not yet recruiting

  OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.

  2025-524003-68-00· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Recruiting

  CLE-PAD : Prevalence of PAD in Patients With Surgically Lumbar Spinal Stenosis

  NCT07469020· Rennes University Hospital· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring

  2024-519133-29-00· Phase 2· Fondation A De Rothschild· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Not yet recruiting

  Strategies for Weaning From External Ventricular Drainage

  NCT07630051· University Hospital, Angers· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Recruiting

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity

  NCT07378072· Nantes University Hospital· Source

• Not yet recruiting

  Liquid Biopsy in Early Colorectal Lesions

  NCT07319104· University Hospital, Montpellier· Source

• Recruiting

  A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

  NCT07189325· Phase 3· University Hospital, Montpellier· Source

• Recruiting

  Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

  NCT07333066· Phase 3· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Recruiting

  Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

  NCT07418827· Assistance Publique Hopitaux De Marseille· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

Showing 50 of 419.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer42 recruiting
• Childhood cancers31 recruiting
• Multiple sclerosis15 recruiting
• Acute myeloid leukaemia11 recruiting
• Colorectal cancer11 recruiting
• Epilepsy11 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Crohn's disease9 recruiting
• Stroke9 recruiting
• Heart failure7 recruiting
• Multiple myeloma7 recruiting
• Systemic sclerosis (scleroderma)7 recruiting
• Amyloidosis6 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• Idiopathic pulmonary fibrosis6 recruiting
• Aortic stenosis5 recruiting
• Follicular lymphoma5 recruiting
• High blood pressure5 recruiting
• Myelodysplastic syndromes5 recruiting
• Myeloproliferative neoplasms5 recruiting
• Ulcerative colitis5 recruiting
• Atrial fibrillation4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Liver and biliary tract cancer4 recruiting
• Obesity4 recruiting
• Prostate cancer4 recruiting
• Alzheimer disease3 recruiting
• Chronic myeloid leukaemia3 recruiting
• Coronary artery disease3 recruiting
• Dilated cardiomyopathy3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Kidney cancer3 recruiting
• Mantle cell lymphoma3 recruiting
• Neuroendocrine tumours3 recruiting
• Sarcoma3 recruiting
• ANCA-associated vasculitis2 recruiting
• Aplastic anaemia2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Bladder cancer2 recruiting
• Brain aneurysm2 recruiting
• COPD2 recruiting
• Haemophilia2 recruiting
• HIV2 recruiting
• Hodgkin lymphoma2 recruiting
• Liver cirrhosis2 recruiting
• Mesothelioma2 recruiting
• Neuromyelitis optica (NMOSD)2 recruiting
• Pancreatic cancer2 recruiting
• Sarcoidosis2 recruiting
• Tuberculosis2 recruiting
• Aortic aneurysm1 recruiting
• Asthma1 recruiting
• Barrett's oesophagus1 recruiting
• Bronchiectasis1 recruiting
• Cerebral palsy1 recruiting
• Chronic kidney disease1 recruiting
• Congenital heart disease1 recruiting
• Cystic fibrosis1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Endometrial cancer1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Glioblastoma1 recruiting
• Gout1 recruiting
• Hepatitis B1 recruiting
• Hidradenitis suppurativa1 recruiting
• Hydrocephalus1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• IgA nephropathy1 recruiting
• Irritable bowel syndrome1 recruiting
• Melanoma1 recruiting
• Myocarditis1 recruiting
• Neuroblastoma1 recruiting
• Osteoporosis1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Sickle cell disease1 recruiting
• Thyroid cancer1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· Phase 2· Merus B.V.· Source

• Completed

  PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

  2024-519258-35-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Completed

  A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

  2024-519651-28-00· Phase 1· CureVac SE· Source

• Completed

  A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor

  2024-517987-46-00· Phase 2· Bioprojet Pharma· Source

• Completed

  Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

  NCT05828303· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

  NCT06444113· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

  NCT05330455· Phase 1/2· Glaxosmithkline Research & Development Limited· Source

• Completed

  ALS Phase II Study of NX210c

  NCT06365216· Phase 2· Axoltis Pharma· Source

• Completed

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Active, not recruiting

  Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma

  NCT05901194· Phase 1/2· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

  2024-513515-27-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Completed

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Terminated

  A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

  NCT06241573· Phase 2/3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

• Completed

  Phosphoproteomic Profile of Children With Down Syndrome

  NCT06279208· Perha Pharmaceuticals· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Novartis Pharma AG· Source

• Completed

  Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

  NCT06080399· University Hospital, Toulouse· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source

• Completed

  Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy

  2022-502316-36-00· Phase 4· Myokardia Inc.· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)

  NCT05604170· Phase 3· Marinus Pharmaceuticals Inc.· Source

• Completed

  Intubation of Obese Patients in the Operating Room With or Without Face Mask Ventilation

  NCT05930678· Nantes University Hospital· Source

• Completed

  Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

  NCT05923827· Insulet Corporation· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source

• Terminated

  Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

  NCT05900050· Phase 2· Genfit· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  Ophthalmological Adverse Events of Tralokinumab in AD

  NCT05682976· Nantes University Hospital· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO)

  2022-501586-50-00· Phase 3· Amgen Inc.· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Comparison in New Cochlear Implanted Subjects of a Tonotopy-based Fitting With or Without Fine Structure Coding

  NCT05754918· MED-EL Elektromedizinische Geräte GmbH· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1

  2022-500905-42-00· Phase 1· University Hospital Grenoble· Source

• Active, not recruiting

  ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

  NCT05650879· Phase 1· Enliven Therapeutics· Source

• Completed

  A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation

  NCT05480865· Phase 1· Navire Pharma Inc.· Source

• Completed

  Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial

  2022-501179-23-00· Phase 4· Centre Hospitalier Universitaire De Nantes· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Nantes University Hospital· Source

• Completed

  First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients

  2022-501183-17-00· Phase 1/2· Inhatarget Therapeutics· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Recruiting

  Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

  NCT04789850· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

  NCT05462522· Phase 1· Genentech, Inc.· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

  NCT05630807· Phase 3· GlaxoSmithKline· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

Showing 50 of 146.

Conditions

Diseases this institution publishes on or runs trials for.

• Systemic sclerosis (scleroderma)31 works · 17 trials
• Amyloidosis17 works · 9 trials
• Hypertrophic cardiomyopathy10 works · 5 trials
• Haemophilia9 works · 7 trials
• Aplastic anaemia4 works · 2 trials
• Mantle cell lymphoma4 works · 8 trials
• Lyme disease3 works · 0 trials